serotonin

By separating therapeutic neuroplasticity from hallucinations, new psychedelic-inspired molecules could make treatment safer and more accessible.

Short-acting psychedelics like bretisilocin could offer rapid, lasting relief for patients with major depressive disorder.

Unlike in other brain regions, levels of the neurotransmitter decrease in the cerebellum when anxiety is high, suggesting a potential new drug target.